Autonomix Medical, Inc. financial data

Symbol
AMIX on Nasdaq
Industry
Surgical & Medical Instruments & Apparatus
Location
21 Waterway Avenue, Suite 300, The Woodlands, TX
State of incorporation
DE
Fiscal year end
March 31
Latest financial report
10-Q - Q4 2024 - Feb 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 669 %
Debt-to-equity 31.9 %
Return On Equity -212 % -126%
Return On Assets -161 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2.46M shares -86.9%
Common Stock, Shares, Outstanding 2.46M shares -82.9%
Common Stock, Value, Issued 2K USD -85.7%
Weighted Average Number of Shares Outstanding, Basic 1.85M shares +82.6%
Weighted Average Number of Shares Outstanding, Diluted 13.8M shares +15%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
Research and Development Expense 3.87M USD +52%
General and Administrative Expense 6.88M USD -23.9%
Operating Income (Loss) -10.8M USD +6.05%
Nonoperating Income (Expense) -2.88M USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -13.6M USD +12.9%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -13.6M USD -27.6%
Earnings Per Share, Basic 6.8 USD/shares +52.4%
Earnings Per Share, Diluted -0.23 USD/shares -360%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 11.8M USD
Other Assets, Current 109K USD -76.7%
Assets, Current 11.9M USD +608%
Property, Plant and Equipment, Net 20K USD +42.9%
Assets 12M USD +561%
Accounts Payable, Current 232K USD -65%
Accrued Liabilities, Current 881K USD +184%
Liabilities, Current 2.25M USD +131%
Other Liabilities, Noncurrent 4.97M USD
Liabilities 2.25M USD -69.7%
Retained Earnings (Accumulated Deficit) -47.2M USD -40.6%
Stockholders' Equity Attributable to Parent 9.71M USD
Liabilities and Equity 12M USD +561%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.85M USD -180%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities -5K USD
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 2.46M shares -82.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.86M USD -190%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.22M USD +50.4%
Deferred Tax Assets, Valuation Allowance 3.46K USD +136%
Deferred Tax Assets, Gross 3.46K USD +136%
Payments to Acquire Property, Plant, and Equipment 5K USD
Deferred Tax Assets, Operating Loss Carryforwards 2.64K USD +96.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 56.9M USD +104%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 43K USD
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Interest Expense 33K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%